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Studies in human immunodeficiency virus (HIV)–infected 
individuals suggest excess weight gain with integrase inhib-
itor–based antiretroviral therapy. The HIV Prevention Trials 
Network Study 077 evaluated changes in weight and fasting met-
abolic parameters in HIV-uninfected individuals randomized 
to cabotegravir or a placebo. No differences between arms were 
found for change in weight or fasting metabolic parameters 
overall or for subgroups.
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Antiretroviral therapy (ART) that contains an integrase inhib-
itor has been associated with weight gain and increased waist 
circumference, with changes of greater magnitude seen among 
women, blacks, and those with lower CD4 and higher human 
immunodeficiency virus (HIV) RNA prior to starting ART [1–
7]. Some studies have observed a mitigating effect of tenofovir 
disoproxil fumarate (TDF) in those regimens [1], and these 
changes have been associated with increases in body mass index 
(BMI) category [8]—a change that has been associated in other 
studies with morbidity and mortality [9].
Cabotegravir (CAB) is a novel integrase inhibitor in develop-
ment for HIV prevention and as part of combination ART for 
treatment. CAB is available both as an oral tablet for daily ad-
ministration (being developed only for lead-in to the injectable 
product) and as a long-acting suspension for monthly or every-
other-month intramuscular injection [10]. Weight changes for 
HIV-infected participants in trials of CAB as part of combina-
tion ART have not yet been published.
The HIV Prevention Trials Network Study 077 (HPTN 
077) was a phase 2a safety, tolerability, and pharmacokinetic
study that enrolled 199 HIV-uninfected low-risk participants at
8 sites globally [11]. The study provides a unique opportunity
to evaluate changes in weight and metabolic parameters among
participants exposed to long-acting injectable CAB (CAB LA)
or a placebo (PBO), absent HIV infection or additional anti-
retroviral agents. We performed a post hoc analysis to explore
the hypothesis that changes in weight and metabolic parameters 




In HPTN 077, participants were randomized 3:1 to CAB or a 
PBO course, during which they received a daily oral tablet for 4 
weeks, a 1-week hiatus, and then a series of injections with a pri-
mary safety and tolerability endpoint 41 weeks after study entry. 
Two dose cohorts were enrolled sequentially, the first with an 
injection phase consisting of 3 quarterly injections of 800 mg 
of CAB (or a 0.9% saline placebo) and the second characterized 
by 5 total injections of 600 mg of CAB (or saline placebo) at 
8-week intervals after a 4-week initial separation. Participants
were then followed for 48–72 weeks after their final injection.
Assessments
Weight was measured at study entry, during oral product admin-
istration at weeks 2 and 4, and during injectable product admin-
istration at weeks 5, 17, 19, 29 or 33, and 41 [1]. Demographics 
were collected at baseline, and BMI was calculated from base-
line height measurement and week 0 (W0) and week 41 (W41) 
weight measurements. Fasting glucose and fasting lipids were 
collected at W0 and W41.
Analysis
Wilcoxon rank sum tests were used to compare distributions 
of intraparticipant changes in weight and metabolic 
parameters; only participants with paired W0 and W41 data 
available for a given parameter were included. Generalized 
estimating equations (GEE) were used to model longitudinal 
weight data over time. Mean modeled intraparticipant weight 
changes were compared between CAB and PBO groups as 
an additional sensitivity analysis to the primary comparison. 
The GEE model included all 177 participants and available 
weight data at all available timepoints of interest (above) for 
a given participant.
We estimated that the sample size of 177 participants pro-
vided 90% power with a 5% significance alpha to rule out a 
2.4 kg or larger mean difference in overall weight change be-
tween the CAB and PBO arms.
RESULTS
Study and Analysis Population
The numbers of participants who entered the study in each arm 
of each dose cohort and who received each sequential injection 
are shown in Figure 1A. For the current analysis, we included 
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Cohort – Arm Week 0 Inj. 1 Inj. 2 Inj. 3 Inj. 4 Inj. 5
Cohort 1 – CAB, n 82 74 63 59 - -
Cohort 1 – PBO, n 28 25 25 20 - -
Cohort 2 – CAB, n 69 60 59 58 58 55
Cohort 2 – PBO, n 20 18 18 17 17 16
Inj. 1 Inj. 2 Inj. 3
Inj. 1 Inj. 2 Inj. 3 Inj. 4 Inj. 5
CAB PBO
Figure 1. A, HIV Prevention Trials Network study 077 study design. B, Median and interquartile range participant weight by study arm over time. Abbreviations: CAB, 
cabotegravir; IM, intramuscular; Inj, injection; LA, long-acting; PBO, placebo; PO, by mouth (orally); QD, everyday.
The overall study population has been previously described 
[11]; the analysis population (n = 177) had a median age of 31.5 
(interquartile range [IQR], 24–39) years, was 66% female, 40% 
black, and 26% Latino. Slightly more than half (55%) were from 
US sites, 23% from sub-Saharan Africa, and 21% from Brazil. 
Ten percent of the population reported smoking at study entry. 
Characteristics were balanced between the CAB and PBO arms.
The median baseline weight of study participants was 74.7 
(IQR, 62.4–91.2) kg and median BMI was 26.6 (IQR, 23.4–32.7), 
with no significant difference between CAB and PBO groups 
(Figure 1B and Supplementary Figure 1A). At baseline, median 
fasting glucose was 85 (IQR, 80–90) mg/dL. Median total cho-
lesterol, low-density lipoprotein, high-density lipoprotein, and 
triglycerides were 170.5 (IQR, 151–192), 99 (IQR, 80–121), 51 
(IQR, 41–63), and 80 (IQR, 56–121). Baseline fasting meta-
bolic parameters were also not different between CAB and PBO 
treated participants (Supplementary Figure 1C). No participant 
met the fasting glucose criterion for diabetes.
Outcomes
Among the 146 participants with paired weights, between 
W0 and W41 the median increase in weight for CAB-treated 
participants was 1.1 (IQR, –0.9, +3.0) kg; median 1.0 (IQR, –.2, 
+3.2) kg was gained by PBO-treated participants (∆ = +0.1 kg,
P = .66). The distribution of weight changes across the 41-week
treatment period did not differ between CAB- and PBO-
treated participants nor when divided into the W0–W4 oral
phase (∆ = +0.3 kg, P =  .6) and the W5–W41 injection phase
(∆ = +0.2 kg, P = .65). A 5% or greater increase in weight from
W0 to W41 was seen in 24 (22%) CAB participants and in 7
(18%) PBO participants (P = .62).
Distributions of changes in weight from W0 to W41 were 
also not different among racial and ethnic subgroups nor by sex 
at birth, injectable product dose cohort, BMI category (greater 
than or less than or equal to the overall study population me-
dian), or baseline smoking status (Supplementary Figure 2). 
Distributions of changes in weight were also not different across 
geographic region (United States, Brazil, sub-Saharan Africa).
Frequency of transitions between BMI categories (using 
standard definitions) were not significantly different between 
arms (Supplementary Figure 1B). GEE models of all available 
weight data over time were consistent with the sparse analysis 
using only W0 and W41 data (Supplementary Tables 1–3).
Distributions of changes in fasting glucose and lipid 
parameters also were not different between CAB- and PBO-
treated participants (Supplementary Figure 3).
DISCUSSION
Clinical experience, observational cohort data, and randomized 
trials strongly suggest, but do not confirm, an association 
between integrase inhibitor–based ART and weight gain. 
Observational data from treatment studies in persons living 
with HIV have described transitions in BMI category among 
integrase inhibitor–treated participants [8] that have the poten-
tial to increase risk for metabolic complications and increase 
risk for cardio- and cerebrovascular disease and altered glu-
cose homeostasis. These data are potentially confounded by 
the presence of HIV infection and its inflammatory sequalae, 
a return to health phenomenon, as well as potential mitigating 
or exacerbating effects of nucleoside reverse transcriptase 
inhibitors, which are used as “backbones” of ART regimens.
We explored changes in weight and fasting metabolic 
parameters assessed as part of the phase 2 development pro-
gram of CAB LA for HIV prevention. Absent HIV infection 
and potentially confounding additional antiretroviral drugs, we 
found no significant differences in changes in weight or fasting 
metabolic parameters between participants randomized to 
CAB or PBO. The observed weight changes were modest (ap-
proximately 1.0 kg in each arm over approximately 9.5 months).
Important limitations to this analysis are its post hoc ex-
ploratory design, nonstandardization of weight measurement 
across study sites, and the modest sample size of the overall 
study and the subgroups analyzed. Two ongoing double-blind, 
double-dummy phase 3 HIV prevention trials, HPTN 083 
(NCT02720094) and HPTN 084 (NCT03164564), with a 
planned total enrollment of 7700 participants will provide 
more definitive data to address this question.
The modest sample size limited our ability to rule out 
weight change differences smaller than approximately 2.4 kg 
between arms. However, if these negative results are con-
firmed in the larger ongoing phase 3 prevention studies of 
CAB, it is possible that the weight increases seen in treat-
ment studies of HIV-infected individuals are attributable to 
differential effects of integrase inhibitors on the HIV-affected 
immunologic milieu, a molecule-specific (rather than class) 
effect, and/or bystander activity of other antiretrovirals. 
It is also possible that participants who did not receive the 
full complement of injections in each cohort (Figure 1A) 
and therefore were exposed to waning CAB levels over the 
observation period further diluted any metabolic effects. 
TDF/emtricitabine was associated with a 5% or greater un-
intentional weight loss in the iPrEX study [12]; absence of 
weight gain, if confirmed, could increase the acceptability of 
integrase inhibitor–based preexposure prophylaxis. While 
we did not observe a difference in fasting glucose between 
arms, we did not collect fasting insulin/homeostatic model 
assessment for insulin resistance, a more sensitive measure 
for detecting changes in glucose tolerance.
In a moderately sized randomized study of CAB vs PBO 
in HIV-uninfected participants, no differences in changes in 
weight or fasting metabolic parameters were apparent between 
study arms. Ongoing phase 3 efficacy studies of CAB for HIV 
prevention will provide an opportunity to further examine 
these potential relationships.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
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